Can MSOS Reach $5.00? Weighing the +25% Upside for the Cannabis ETF

Key Takeaways

• The $5.00 central target is drawn from public market discussion and technical analysis, not from an analyst consensus, which does not exist for this ETF.
• MSOS recently traded near $4.00, so reaching $5.00 would require a gain of roughly 25%.
• The ETF is highly concentrated, with top holdings Trulieve (TCNNF) and Curaleaf (CURLF) each near 28% of assets and Green Thumb Industries (GTBIF) a close third.
• The strongest support for a move higher is the potential federal rescheduling of cannabis to Schedule III, which could remove the Section 280E tax burden and unlock capital access.
• The biggest risks are regulatory delay or failure, persistent price compression in the industry, and the concentration and leverage embedded in the fund.
• You can explore Major News, Today's Price Move, Forecast, and Earnings for MSOS on additional pages.
• For a broader view of automated market analysis, explore Trending AI Robots.

Establishing the $5.00 Target

Because MSOS is an ETF with no formal analyst price targets, the $5.00 figure is a fallback objective grounded in identifiable public discussion rather than a published consensus. Public commentary from Seeking Alpha contributors has pointed to a reversion of the ETF's portfolio toward its historical multiple of about 2x sales, implying a target near $4.45. Separately, technical commentary has referenced higher retests of the fund's recent trading range. The $5.00 level is a clean, widely watched round-number milestone that sits just below the ETF's recent one-month high near $5.44 and well below its 52-week high of $7.25. It represents a realistic recovery scenario, not an aggressive multi-year projection. From what I see, this level serves as a useful benchmark for tracking sector sentiment.

Current Market Position and Path Toward the Target

MSOS recently traded near $4.00, with a net asset value (NAV) around $4.08 and a 52-week range of $2.96 to $7.25. Reaching $5.00 would require a move of roughly 25%, a substantial gain that would still leave the fund below its 52-week high and far below its 2021 all-time peak near $55.91. The path to $5.00 likely depends less on earnings momentum and more on a re-rating of the underlying operators. If investors grow confident that Section 280E tax treatment will be removed, cash-flow and net-income estimates across the portfolio would improve materially, potentially justifying higher equity values even without dramatic revenue acceleration.

What Could Support a Move Toward the Target

The dominant catalyst is federal rescheduling of cannabis from Schedule I to Schedule III. Such a change would eliminate the Section 280E restriction that currently prevents cannabis operators from deducting ordinary business expenses, a burden that has suppressed profitability across the industry. Related tailwinds include the possibility of broader banking access through legislation such as the SAFE Banking Act, eventual uplisting of operators to major exchanges, and a proposed Medicare pilot program that lends legitimacy to reform efforts. Public valuation work notes the portfolio traded near 1.7x sales, below its historical average of about 2x, suggesting room for multiple expansion if sentiment improves. ETF inflows and a rebound in sector momentum would provide additional support. I also checked comparable holdings using Tickeron’s AI Screener to see how the sector stacks up.

What Could Prevent the Target From Being Reached

The principal risk is regulatory disappointment. Rescheduling has been repeatedly delayed, and actions by the DEA (Drug Enforcement Administration) and FDA could stall the process for years, or it could be challenged in court. If Section 280E tax treatment remains in place, many operators face persistent debt and margin pressure. The industry also contends with state-level price compression and oversupply, while MSOS itself carries structural risks: its top three holdings represent roughly 60–70% of assets, concentrating single-name risk, and the fund has used modest leverage through swaps, which can amplify volatility. Redemption pressure, which forces the fund to sell its largest, thinly traded positions, is an additional headwind.

Technical Levels and Market Structure

Technically, MSOS has been choppy, trading below both its 20-day and 200-day moving averages after a sharp pullback from its recent range. Nearby resistance has been observed in the $4.34 to $4.47 zone, with the $5.00 level serving as the next meaningful round-number hurdle and the one-month high near $5.44 acting as a deeper recovery marker. On the downside, support has appeared around the $4.10 area, with the 52-week low near $2.96 representing a more durable floor. The broader structure remains one of lower highs over recent months, so a sustained move toward $5.00 would likely require a decisive break above the $4.47 resistance area.

Time Horizon and What Investors Should Monitor

Because this target comes from public discussion rather than formal analyst research, there is no standard 12-month horizon attached to it. Investors should monitor developments in the rescheduling process, including DEA and FDA actions, any legislative movement on banking reform, and the rollout of the Medicare pilot program. Quarterly results from the fund's largest holdings are also key, particularly their guidance on margins and any change in 280E tax provisioning. ETF-level items to watch include changes in shares outstanding, which signal inflows or redemptions, and shifts in the fund's top holdings.

AI Daily Buy/Sell Signals for Tracking MSOS

In my own process, I find it helpful to cross-reference signals from Tickeron’s AI Daily Buy/Sell Signals when following volatile names like this ETF. The tool applies artificial intelligence to scan thousands of securities and deliver Buy, Sell, or Hold signals based on technical and market shifts. It provides an objective layer that complements fundamental and regulatory analysis, particularly useful for catalyst-driven sectors where timing matters.

Final Assessment

The $5.00 target for MSOS is a public-discussion objective rooted in a potential re-rating of U.S. cannabis operators, not an analyst consensus. From a recent price near $4.00, reaching it would require a substantial move of about 25%. The case rests almost entirely on federal rescheduling removing the Section 280E tax burden and unlocking capital access; against that stand the real possibility of regulatory delay, industry price compression, and the ETF's heavy concentration and modest leverage. There is no guarantee the fund reaches $5.00, but the level is a reasonable benchmark for investors to track as they weigh regulatory headlines, holdings-level earnings, and fund flows.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Industry description

Market Cap

High and low price notable news

Volume